| NCT ID | NCT05561205 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sunnybrook Health Sciences Centre |
| Condition | Alzheimer Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2023-02-09 |
| Primary Completion | 2026-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 10 participants in total. It began in 2023-02-09 with a primary completion date of 2026-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Apathy is a common, early, and disabling symptom in dementias and mild behavioural impairment such as Alzheimer's disease (AD) and is characterized by lack of interest and enthusiasm. Both repetitive transcranial magnetic stimulation (rTMS), a form of non-invasive brain stimulation, and methylphenidate, a medication, have been shown to improve apathy. This pilot study will investigate rTMS as a treatment for apathy in neurocognitive disorders and mild behavioural impairment in individuals receiving methylphenidate and individuals not receiving medication for apathy.
Eligibility Criteria
Inclusion Criteria: * mild or major neurocognitive disorder OR mild behavioural impairment * Apathy for at least 4 weeks * Stable dose of medication (\>4 weeks) that may affect cognition or behaviour * Care partner who spends at least 10 hours a week with the subject Exclusion Criteria: * Current major depressive episode * Agitation, delusions, hallucination * Medical contraindications to rTMS * Currently taking an amphetamine product * Central nervous system abnormalities, Tourette's syndrome, or motor tics * Current participation in another clinical trial
Frequently Asked Questions
Who can join the NCT05561205 clinical trial?
This trial is open to participants of all sexes, studying Alzheimer Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05561205 currently recruiting?
Yes, NCT05561205 is actively recruiting participants. Visit ClinicalTrials.gov or contact Sunnybrook Health Sciences Centre to inquire about joining.
Where is the NCT05561205 trial being conducted?
This trial is being conducted at Toronto, Canada.
Who is sponsoring the NCT05561205 clinical trial?
NCT05561205 is sponsored by Sunnybrook Health Sciences Centre. The trial plans to enroll 10 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.